Key facts
- Greenstone Biosciences’s last known valuation is $123.0M (May 2025).
- It has raised $20.2M across 1 recorded rounds; the latest was Early Stage VC ($10.2M) in Apr 2022.
- Notable investors include National Institutes of Health, Aramco Ventures, A&E Investments, Walden Catalyst, California Institute for Regenerative Medicine.
- Greenstone Biosciences has filed 1 Form D with the SEC, most recently May 2022 ($10.2M sold to 20 investors).
- Status: Privately Held (backing).
- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 5 names
- ·Watchlist + deal alerts for Greenstone Biosciences
Funding rounds
1 roundsAbout Greenstone Biosciences
Operator of a drug discovery platform intended to accelerate the development of effective therapies for patients. The company's platform uses artificial intelligence or machine learning computing and human-induced pluripotent cells technology to transform drug discovery from a slow, sequential and high-failure process into a rapid, integrated and novel computational platform, enabling patients with safe and effective therapeutics for diseases with urgent unmet needs.
- Sector
- Healthcare
- HQ
- Palo Alto, CA, United States
- Founded
- 2021
- Employees
- 19
- Website
- greenstonebio.com/
- Ownership
- Privately Held (backing)
Greenstone Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Greenstone Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Greenstone Biosciences in its N-PORT filings yet. We sweep new filings monthly.